Monkeypox Vaccine, Drug Pipeline Grows Despite Signs Of Slowing Infections

Most Products Remain In Preclinical Development

Since its emergence in the spring, the monkeypox outbreak has spawned a small but growing pipeline of drugs and vaccines, many of them repurposed smallpox products.

The monkeypox outbreak has spawned a small but growing pipeline of vaccines and drugs • Source: Shutterstock

Since it began spreading in the spring and migrated to the US shortly thereafter, monkeypox has yet to explode from an outbreak into a bigger epidemic, let alone a pandemic, and infection rates are already showing signs of plateauing in many areas. Still, the world isn’t out of the woods yet, with large-scale growth of infections still possible. To that end, a small pipeline of drug and vaccine candidates has emerged, many of them repurposed products originally developed for smallpox, despite some hitches in getting programs off the ground.

The US Centers for Disease Control has reported 21,504 cases of monkeypox in the US, while the World Health Organization reported 52,996 cases across 102 countries between 1 January and 7 September. WHO director-general Tedros Adhanom Ghebreyesus said in 25 August remarks that the epicenter of the outbreak had moved from Europe to the Americas

More from Anti-infective

More from Therapy Areas

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By 

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By 

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.